The price of a cancer medicine is not a footnote in a patient's treatment. For lakhs of Indian families, it is the difference between treatment and ruin, between a full course of therapy and a course abandoned halfway because the money ran out. That is why the sharp falls now appearing in the prices of cancer drugs matter so much, and why health experts say those falls expose something uncomfortable about how medicines were priced in the first place.
The National Pharmaceutical Pricing Authority, the government's drug price regulator, issued an order on October 17 capping trade margins at thirty per cent on one hundred and thirty-seven non-scheduled anti-cancer drugs.
The order used the regulator's extraordinary powers under Paragraph 19 of the Drugs (Prices Control) Order of 2013, which allows intervention in the public interest for drugs that are not on the National List of Essential Medicines and are therefore not subject to ordinary price fixation.
Companies were required to set new maximum retail prices based on the average price charged to distributors in March 2026, with the permitted trade margin capped at thirty per cent plus applicable taxes. The revised prices are to take effect on November 9.
A revised price list published by the regulator, based on company filings up to October 27, shows the scale of the change. Of five hundred and forty-three listed brand, strength and pack-size entries, three hundred and ninety-seven now carry lower prices ahead of the deadline. The average reduction among those entries is about fifty per cent.
The government has estimated that the intervention could reduce maximum retail prices by up to seventy per cent in some cases and save patients around two thousand five hundred crore rupees a year.
The individual examples are startling. One brand of palbociclib, used in breast cancer treatment, has fallen from approximately forty thousand four hundred and twenty-one rupees per pack to two thousand seven hundred and twenty rupees, a reduction of about ninety-three per cent. A vial of thiotepa has fallen from approximately eighty thousand and seventy-two rupees to seven thousand one hundred and fifty rupees.
A pack of ten anastrozole tablets, also used for breast cancer, has come down from about four hundred and fifty-nine rupees to under forty rupees. A vial of bevacizumab, approved for colon, ovarian and cervical cancers, has fallen from nearly seventy thousand rupees to about thirteen thousand five hundred rupees. Pertuzumab has dropped from around ninety-five thousand rupees a vial to roughly thirty thousand six hundred rupees.
Abiraterone, used for prostate cancer, has fallen from twenty-eight thousand rupees a pack to under five thousand rupees. Dasatinib, used for leukaemia, has come down from about seventeen thousand eight hundred rupees to roughly one thousand eight hundred rupees. A prefilled syringe of denosumab, used by breast and prostate cancer patients, has fallen from about twenty-two thousand rupees to under six thousand rupees.
Health campaigners argue that falls of this size raise serious questions about the prices patients were charged before.
Jan Swasthya Abhiyan India, an organisation working for access to medicines, said that such drastic reductions raise serious questions about the pricing practices of pharmaceutical companies, including major Indian manufacturers of generic cancer medicines that had reportedly offered substantial trade margins while patients continued to face unaffordable prices.
The group said that controlling trade margins alone is insufficient, and that life-saving cancer treatment must be affordable based on medical need rather than a patient's ability to pay.
The campaigners also criticised the design of the policy itself. They argued that the formula allows a mark-up of forty-two point eight per cent over the price to stockist, which they said legitimises excessive margins, particularly in a supply chain that often involves only one or two intermediaries or direct sales to hospitals.
They pointed out that a substantially lower mark-up, comparable to the sixteen per cent margin applicable to scheduled formulations under the price control framework, could have delivered greater benefits to patients.
They also said that excluding medicines supplied free under patient assistance programmes from the calculations has further limited the policy's impact, and that without permanent, enforceable margin caps, regular monitoring and verification by the regulator, excessive pricing could persist or return. A one-time reduction in maximum retail prices, they warned, is not enough.
The relief, in any case, is uneven. Of the one hundred and ten drugs represented in the filings so far, thirty-five have price reductions across every listed brand, while forty-seven show no change at all, and the remaining twenty-eight have mixed outcomes, with generic and biosimilar versions becoming cheaper while some original brands keep their existing prices.
Several expensive patented treatments, including Keytruda, nivolumab and osimertinib, remain unchanged, limiting the relief for patients on newer therapies. The original brand of olaparib, sold as Lynparza, remains at forty thousand six hundred and twenty rupees for the hundred milligram strength, while a generic brand has fallen sharply.
That pattern reflects a familiar feature of the Indian market: competition among generic and biosimilar makers drives prices down, while single-brand patented medicines, facing no competition, stay expensive.
The story behind the price cap goes back years. In 2019, the regulator had used the same extraordinary powers to cap trade margins at thirty per cent for forty-two non-scheduled anti-cancer drugs. The government subsequently reported that the intervention reduced the maximum retail prices of five hundred and twenty-six brands by up to ninety per cent, generating estimated annual savings of approximately nine hundred and eighty-four crore rupees for patients.
But after that successful pilot, nothing more was done for nearly eight years, even though the same logic plainly applied to a much longer list of drugs.
The matter returned to the spotlight in the Supreme Court. On September 29, 2026, a bench of Justices Vikram Nath and Sandeep Mehta expressed grave concern over excessive mark-ups on cancer medicines while hearing a public interest litigation brought by Jan Swasthya Abhiyan, which had been before the court for five years. The bench questioned practices under which hospitals charged patients many times over their procurement costs.
One judge pointed to a nearly ten-fold mark-up on an essential cancer drug, supplied to retailers for around three thousand rupees but sold to consumers for twenty-seven thousand rupees, and asked who ultimately benefited from the difference of nearly twenty-four thousand rupees. The bench described the situation bluntly, observing that steep mark-ups placed an enormous burden on taxpayers.
The human context makes the numbers harder to ignore. Around sixty people per one lakh population are affected by cancer in India, and out-of-pocket expenditure accounts for around seventy-five per cent of total cancer-treatment expenditure. For a family facing a diagnosis, the cost of medicines is often the largest single expense, and it arrives at the worst possible moment, when earning capacity may already be falling.
The government's own estimate of two thousand five hundred crore rupees in annual savings gives a sense of the scale of what patients were paying above the new capped prices.
What happens after November 9 will matter as much as the new prices themselves. Companies must maintain their present production levels, so that cheaper prices do not lead to shortages, and the regulator will need to verify that the revised prices are actually charged.
Campaigners want the government to go further, moving from a one-time margin cap towards cost-based price control and permanent caps, so that the next round of price falls does not require another court case and another eight-year wait.
For patients and their families, the immediate news is welcome: hundreds of cancer drug brands are about to become much cheaper. But the deeper question raised by the price cuts will not go away. If a medicine can fall by ninety per cent and still be sold profitably, what were patients paying for all those years? Until that question is answered with a system that keeps prices fair permanently, the relief, however real, will feel incomplete.
(Reporting based on The Hindu and The Hindu BusinessLine.)